Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) - Trial NCT06066424
Access comprehensive clinical trial information for NCT06066424 through Pure Global AI's free database. This Phase 1 trial is sponsored by M.D. Anderson Cancer Center and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 54 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 1
Oct 24, 2023
Apr 30, 2040
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Summary
To find the recommended dose of TROP2- CAR-NK cells that can be given to patients with
 advanced forms of solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06066424
Non-Device Trial